UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): June 15, 2021
SCYNEXIS, Inc.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
|
|
Delaware |
|
001-36365 |
|
56-2181648 |
|
(State or Other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
1 Evertrust Plaza, 13th Floor
Jersey City, New Jersey 07302-6548
(Address of Principal Executive Offices, and Zip Code)
(201)-884-5485
Registrant’s Telephone Number, Including Area Code
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
|
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
Common Stock, par value $0.001 |
|
SCYX |
|
Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security Holders.
On June 15, 2021, SCYNEXIS, Inc. held its 2021 Annual Meeting of Stockholders. The following is a brief description of each matter voted upon at the Annual Meeting, as well as the final tally of the number of votes cast: (a) for or withheld with respect to the election of directors; (b) for, against or abstain for the ratification of the appointment of Deloitte & Touch LLP as SCYNEXIS’s independent registered public accounting firm for the fiscal year ending December 31, 2021; and (c) for, against or abstain for the advisory approval of the executive compensation as disclosed in SCYNEXIS’s proxy statement, filed with the Securities and Exchange Commission on April 26, 2021 (the “Proxy Statement”). Broker non-votes are also reported. A more complete description of each matter is set forth in the Proxy Statement.
|
Proposal 1: |
Each of the seven directors proposed by SCYNEXIS for re-election was elected to serve until SCYNEXIS’s 2022 Annual Meeting of Stockholders or until his or her respective successor has been elected and qualified. The tabulation of votes on this matter was as follows: |
||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
For |
|
Withheld |
|
Broker
|
|||||||||||
|
Armando Anido |
|
|
|
4,749,119 |
|
|
|
|
3,602,789 |
|
|
|
|
5,228,697 |
|
||
|
Steven C. Gilman, Ph.D. |
|
|
|
8,139,574 |
|
|
|
|
212,334 |
|
|
|
|
5,228,697 |
|
||
|
Ann F. Hanham, Ph.D. |
|
|
|
7,991,370 |
|
|
|
|
360,538 |
|
|
|
|
5,228,697 |
|
||
|
David Hastings |
|
|
|
5,796,251 |
|
|
|
|
2,555,657 |
|
|
|
|
5,228,697 |
|
||
|
Guy Macdonald |
|
|
|
8,104,440 |
|
|
|
|
247,468 |
|
|
|
|
5,228,697 |
|
||
|
Marco Taglietti, M.D. |
|
|
|
8,109,778 |
|
|
|
|
242,130 |
|
|
|
|
5,228,697 |
|
||
|
Philippe Tinmouth |
|
|
|
8,105,257 |
|
|
|
|
246,651 |
|
|
|
|
5,228,697 |
|
||
|
Proposal 2: |
The appointment of Deloitte & Touch LLP as SCYNEXIS’s independent registered public accounting firm for the fiscal year ending December 31, 2021, was ratified. The tabulation of votes on this matter was as follows: |
|
|
|
|
|
|
|
|
|
For |
|
Against |
|
Abstain |
|
Broker
|
|
13,225,660 |
|
165,390 |
|
189,555 |
|
— |
|
Proposal 3: |
The executive compensation, as disclosed in the Proxy Statement, was approved. The tabulation of votes on this matter was as follows: |
|
|
|
|
|
|
|
|
|
For |
|
Against |
|
Abstain |
|
Broker
|
|
7,778,910 |
|
418,583 |
|
154,415 |
|
5,228,697 |
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
SCYNEXIS, Inc. |
||
|
|
|
|
|
|||
|
Date: June 15, 2021 |
|
|
|
By: |
|
/s/ Marco Taglietti |
|
|
|
|
|
Name: |
|
Marco Taglietti, M.D. |
|
|
|
|
|
Its: |
|
Chief Executive Officer |